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St. John’s wort (SJW), a widely used
herbal product, has been implicated
in drug interactions resulting from
the induced expression of the cyto-
chrome P450 CYP3A4 isoform. In
this study, we determined the effect of
SJW on the metabolism of irinotecan,
a pro-drug of SN-38 and a known
substrate for CYP3A4. Five cancer
patients were treated with irinotecan
(350 mg/m2, intravenously) in the
presence and absence of SJW (900 mg
daily, orally for 18 days) in an un-
blinded, randomized crossover study
design. The plasma levels of the active
metabolite SN-38 decreased by 42%
(95% confidence interval [CI] = 14%
to 70%) following SJW cotreatment
with 1.0 µM × h (95% CI = 0.34 µM
× h to 1.7 µM × h) versus 1.7 µM × h
(95% CI = 0.83 µM × h to 2.6 µM × h)
(P = .033, two-sided paired Student’s
t test). Consequently, the degree of
myelosuppression was substantially
worse in the absence of SJW. These
findings indicate that patients on iri-
notecan treatment should refrain
from taking SJW because plasma lev-
els of SN-38 were dramatically re-
duced, which may have a deleterious
impact on treatment outcome. [J Natl
Cancer Inst 2002;94:1247–9]
St. John’s wort (SJW) has become
one of the world’s most popular herbal
preparations, particularly among cancer
patients (1) because of its alleged activ-
ity in mild to moderate forms of depres-
sion (2–4). Previous case reports and
clinical investigations suggest that SJW
induces the expression of the cyto-
chrome P450 enzyme system and drug-
transporting proteins (5–8). Specifically,
SJW was shown to directly induce the
expression of the cytochrome P450
CYP3A4 isoform in intestinal and he-
patic cells and to induce the expression
of MDR1 P-glycoprotein in intestinal
cells (9–11). These observations might
have profound clinical implications for
patients with colorectal cancer receiving
the chemotherapy agent irinotecan, be-
cause the drug is, in part, eliminated via
CYP3A4- and P-glycoprotein-mediated
routes (12). Moreover, irinotecan, a to-
poisomerase I inhibitor, has a narrow
therapeutic range, and the induction of
CYP3A4 and P-glycoprotein by SJW
might theoretically result in decreased
systemic levels of the pharmacologi-
cally active metabolite SN-38, the con-
sequence of which might be a loss of
antitumor activity.
We evaluated the potential of SJW to
affect plasma concentrations of SN-38
in a group of cancer patients treated with
irinotecan in an unblinded, randomized
crossover study design, with and with-
out SJW coadministration. The clinical
protocol was approved by the Erasmus
MC Ethics Board, and all patients
signed informed consent forms before
study entry. Irinotecan was administered
once every 3 weeks as a 90-minute con-
tinuous intravenous infusion at a dose of
350 mg/m2. Fourteen days before the
start of the first or second irinotecan ad-
ministration, patients received one SJW
tablet (300 mg; Bio Nutrition Health
Products, Den Bosch, The Netherlands)
three times a day (i.e., one tablet with
each meal). The patients continued this
comedication while receiving the irino-
tecan therapy and stopped 4 days after
irinotecan dosing. Patients were asked to
abstain from alcohol, caffeine, grape-
fruit juice, other herbal dietary supple-
ments, and/or substances known to in-
fluence the expression of CYP3A4 for a
period of 2 weeks before the first irino-
tecan administration up to 3 weeks after
the second irinotecan administration.
Blood sampling, drug analyses, and
pharmacokinetic parameter calculations
were performed as described (13,14).
Data are presented as mean value with
95% confidence intervals (CIs), and sta-
tistical calculations were performed on
the Number Cruncher Statistical System
(NCSS), version 5.X (J. L. Hintze, East
Kaysville, UT).
There were five evaluable patients:
two men and three women, with a me-
dian age of 58 years (range  54–66
years) and a median World Health Or-
ganization (WHO) performance score of
1 (range  0–1) (http://www.who.int/
home-page/). All five completed the
study within the scheduled time without
delay. Two patients had colorectal can-
cer, two had lung cancer, and one had
sarcoma. Clinically, irinotecan-induced
neutropenia, as measured by a decrease
in the number of circulating neutrophils,
was the most prominent side effect, and
the spectrum of side effects was un-
changed by SJW. The degree of myelo-
suppression differed substantially be-
tween the treatment course with
irinotecan alone and the combination
course with irinotecan and SJW. At na-
dir, leukocyte and neutrophil counts de-
creased 56% (95% CI  32% to 80%)
and 63% (95% CI  48% to 78%), re-
spectively, during the course with irino-
tecan alone but decreased only 8.6%
(95% CI 0% to 29%) and 4.3% (95%
CI  0% to 20%), respectively, during
the combination course with irinotecan
and SJW.
We next measured the levels of the
active irinotecan metabolite SN-38 and
its CYP3A4-mediated detoxified me-
tabolite 7-ethyl-10-[4-N-(5-aminopenta-
noic acid)-1-piperidino]-carbonyl-oxy-
camptothecin (APC). Compared with
courses of irinotecan alone, the area un-
der the curve (AUC) of SN-38 decreased
by 42% (95% CI 14% to 70%) in the
combination course with irinotecan and
SJW from 1.7 M × h (95% CI 0.83
M × h to 2.6 M × h) to 1.0 M × h
(95% CI 0.34 M × h to 1.7 M × h)
(P  .033, two-sided Student’s t test;
Fig. 1 and Table 1). Surprisingly, the
AUC ratio of APC to irinotecan was also
reduced by 28% (95% CI 0% to 80%)
in the combination course with irinote-
can and SJW, although this reduction
was not statistically significant. This re-
sult suggests that the induction of
CYP3A4 expression results in the for-
mation of presently unknown metabo-
lites other than APC (15), as has been
described previously (16) in pediatric
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high-grade glioma patients treated with
irinotecan and CYP3A4-inducing anti-
convulsants. Alternatively, the lack of
effect on APC might be attributed to the
fact that during both treatment courses,
patients were receiving dexamethasone.
Dexamethasone is another known in-
ducer of CYP3A4 expression and might
already stimulate APC formation during
the course without SJW cotreatment
(17). In the liver, SN-38 can be metabo-
lized to a glucuronic acid conjugate
(SN-38G), a process that is catalyzed by
uridine diphosphate glucuronosyltrans-
ferases (UGTs). The rate of SN-38 gluc-
uronidation (i.e., the AUC ratio of SN-
38G to SN-38) was not influenced by
SJW (Table 1), suggesting that in-
creased glucuronidation through the in-
duction of UGT was not contributing to
the reduced SN-38 levels.
Similar changes in SN-38 levels
(peak plasma concentrations and AUCs)
were noted among all patients, regard-
less of when they received SJW. The
changes were, however, more pro-
nounced for the three patients who re-
ceived SJW during the second course of
irinotecan than for those who received
SJW during the first course. Previous
work (18) has shown that the ability of
SJW to induce CYP3A4 expression
is dependent on the length of therapy,
with no observable effects when SJW
was given for 8 days or less. It has been
hypothesized that this may be the re-
sult of the formation of an intermediate
or slowly accumulating metabolite
of the components of SJW [i.e., (pseu-
do)hypericin and hyperforin] with
CYP3A4-inducing effects (19). Thus,
one potential explanation for the sched-
ule-dependent effects of SJW on irino-
tecan metabolism may be a prolonged
effect of SJW on CYP3A4 expression
with long-term administration regimens.
It has also been proposed that induc-
tion of MDR1 P-glycoprotein expres-
sion may be a component of the mecha-
nism for interactions between several
other drugs and SJW (11). Preclinical
studies have shown that biliary transport
of SN-38 is unchanged in mice lacking
mdr1-type P-glycoprotein, which sug-
gests no major role of MDR1 P-glyco-
protein in the elimination of SN-38 in
patients (20). These observations, to-
gether with our current observation that
the half-lives of SN-38 are unchanged in
the presence and absence of SJW coad-
ministration (Table 1), make it unlikely
that MDR1 P-glycoprotein is involved
in the observed interaction. This is be-
cause a prominent role of MDR1 P-gly-
coprotein in the interaction would be as-
sociated with increased biliary transport
of SN-38, resulting in a decreased half-
life of SN-38 in plasma.
Overall, our findings suggest that iri-
notecan metabolism and toxicity are al-
tered by SJW and that the two agents
cannot be given safely in combination
without compromising overall antitumor
activity. We expect that the results pre-
sented here for irinotecan are represen-
tative of other anticancer drugs that are
at least partial substrates for CYP3A4.
This hypothesis is supported by recent
observations that the pharmacokinetics
of several commonly used agents, in-
cluding taxanes [e.g., paclitaxel (21)]
and camptothecines [e.g., irinotecan
(22) and topotecan (23)], are altered in
patients on anticonvulsants as a result of
CYP3A4 induction, which leads to in-
creased dose requirements to achieve
similar pharmacologic effects. Until
specific dosing guidelines are available,
it is strongly recommended that patients
Fig. 1. Effect of St. John’s wort (SJW) on the plasma concentration of the active irinotecan
metabolite SN-38 over time. The plasma concentration of SN-38 was measured over time as described
(13,14). Each data point represents an individual data time point of the plasma concentration of SN-38
measured in the absence (closed symbols; solid line) and presence (open symbols; dotted line) of SJW.
The lines represent computer fits of the SN-38 concentration–time curves in the absence and presence of
SJW, respectively.
Table 1. Effect of St. John’s wort (SJW) on irinotecan metabolism*
Parameter Irinotecan (95% CI) Irinotecan/SJW (95% CI) P†
Irinotecan
AUC (M × h) 33 (5.0 to 60) 29 (6.6 to 52) .14
CL (L/h) 36 (8.7 to 64) 40 (9.3 to 71) .11
Cmax (M) 6.2 (4.8 to 7.5) 4.9 (1.3 to 8.5) .35
SN-38‡
AUC (M × h) 1.7 (0.83 to 2.6) 1.0 (0.34 to 1.7) .033
Cmax (M) 0.19 (0.12 to 0.28) 0.11 (0.044 to 0.17) .016
t1/2(z) (h) 26 (0 to 72) 20 (6.1 to 34) .52
AUC ratios
SN-38/irinotecan‡ 0.054 (0.036 to 0.073) 0.036 (0.0054 to 0.067) .054
SN-38G/SN-38 3.2 (2.6 to 3.8) 3.4 (2.6 to 4.3) .33
APC/irinotecan 0.33 (0 to 0.97) 0.23 (0 to 0.55) .31
*AUC  area under the plasma concentration versus time curve; APC  7-ethyl-10-[4-N-(5-amino-
pentanoic acid)-1-piperidino]-carbonyloxycamptothecin; CI confidence interval; CL apparent clear-
ance; Cmax  peak plasma concentration; t1/2(z)  apparent half-life of the terminal disposition phase.
†Two-sided Student’s t test for matched pairs.
‡SN-38 is the active metabolite of irinotecan, also known as CPT-11. SN-38G is a detoxified metabolite
of SN-38 that involves uridine diphosphate glucuronosyltransferase. APC is a detoxified metabolite of
irinotecan that involves the CYP3A4 isoform of cytochrome P450.
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receiving chemotherapeutic treatments
with such agents refrain from taking
SJW.
REFERENCES
(1) Ernst E. A primer of complementary and al-
ternative medicine commonly used by cancer
patients. Med J Aust 2001;174:88–92.
(2) Fetrow CW, Avila JR, editors. Professional’s
handbook of complementary and alternative
medicines. Springhouse (PA): Springhouse;
1999.
(3) Schrader E. Equivalence of St. John’s wort
extract (Ze 117) and fluoxetine: a random-
ized, controlled study in mild–moderate de-
pression. Int Clin Psychopharmacol 2000;15:
61–8.
(4) Stevinson C, Ernst E. Hypericum for depres-
sion. An update of the clinical evidence. Eur
Neuropsychopharmacol 1999;9:501–5.
(5) Johne A, Schmider J, Brockmoller J, Stadel-
mann AM, Stormer E, Bauer S, et al. De-
creased plasma levels of amitriptyline and its
metabolites on comedication with an extract
from St. John’s wort (Hypericum perfora-
tum). J Clin Psychopharmacol 2002;22:
46–54.
(6) Ruschitzka F, Meier PJ, Turina M, Luscher
TF, Noll G. Acute heart transplant rejection
due to Saint John’s wort. Lancet 2000;355:
548–9.
(7) Johne A, Brockmoller J, Bauer S, Maurer A,
Langheinrich M, Roots I. Pharmacokinetic
interaction of digoxin with an herbal extract
from St. John’s wort (Hypericum perfora-
tum). Clin Pharmacol Ther 1999;66:338–45.
(8) Piscitelli SC, Burstein AH, Chaitt D, Alfaro
RM, Falloon J. Indinavir concentrations and
St. John’s wort. Lancet 2000;355:547–8.
(9) Ernst E. Second thoughts about safety of
St. John’s wort. Lancet 1999;354:2014–6.
(10) Roby CA, Anderson GD, Kantor E, Dryer
DA, Burstein AH. St. John’s Wort: effect on
CYP3A4 activity. Clin Pharmacol Ther
2000;67:451–7.
(11) Durr D, Stieger B, Kullak-Ublick GA, Rentsch
KM, Steinert HC, Meier PJ, et al. St. John’s
Wort induces intestinal P-glycoprotein and
hepatic CYP3A4. Clin Pharmacol Ther 2000;
68:598–604.
(12) Mathijssen RH, van Alphen RJ, Verweij J,
Loos WJ, Nooter K, Stoter G, et al. Clini-
cal pharmacokinetics and metabolism of iri-
notecan (CPT-11). Clin Cancer Res 2001;7:
2182–94.
(13) Sparreboom A, de Jonge MJ, de Bruijn P,
Brouwer E, Nooter K, Loos WJ, et al. Irino-
tecan (CPT-11) metabolism and disposition
in cancer patients. Clin Cancer Res 1998;4:
2747–54.
(14) Rivory LP, Haaz MC, Canal P, Lokiec F,
Armand JP, Robert J. Pharmacokinetic inter-
relationships of irinotecan (CPT-11) and its
three major plasma metabolites in patients
enrolled in phase I/II trials. Clin Cancer Res
1997;3:1261–6.
(15) Sai K, Kaniwa N, Ozawa S, Sawada JI. A
new metabolite of irinotecan in which forma-
tion is mediated by human hepatic cyto-
chrome P-450 3A4. Drug Metab Dispos
2001;29:1505–15.
(16) Gajjar AJ, Radomski KM, Bowers DC, Chin-
tagumpala MM, Thompson SJ, Houghton PJ,
et al. Pharmacokinetics of irinotecan (IRN)
and metabolites in pediatric high-grade
glioma patients with and without co-admin-
istration of enzyme-inducing anticonvul-
sants. Proc ASCO 2000;19:162a.
(17) McCune JS, Hawke RL, LeCluyse EL, Gil-
lenwater HH, Hamilton G, Ritchie J, et al. In
vivo and in vitro induction of human cyto-
chrome P4503A4 by dexamethasone. Clin
Pharmacol Ther 2000;68:356–66.
(18) Markowitz JS, DeVane CL, Boulton DW,
Carson SW, Nahas Z, Risch SC. Effect of
St. John’s wort (Hypericum perforatum) on
cytochrome P-450 2D6 and 3A4 activity
in healthy volunteers. Life Sci 2000;66:
PL133–9.
(19) Burstein AH, Horton RL, Dunn T, Alfaro
RM, Piscitelli SC, Theodore W. Lack of ef-
fect of St. John’s Wort on carbamazepine
pharmacokinetics in healthy volunteers. Clin
Pharmacol Ther 2000;68:605–12.
(20) Iyer L, Ramirez J, Shepard DR, Bingham
CM, Hossfeld DK, Ratain MJ, et al. Biliary
transport of irinotecan and metabolites in
normal and P-glycoprotein-deficient mice.
Cancer Chemother Pharmacol 2002;49:
336–41.
(21) Chang SM, Kuhn JG, Rizzo J, Robins HI,
Schold SC Jr, Spence AM, et al. Phase I
study of paclitaxel in patients with recurrent
malignant glioma: a North American Brain
Tumor Consortium report. J Clin Oncol
1998;16:2188–94.
(22) Friedman HS, Petros WP, Friedman AH,
Schaaf LJ, Kerby T, Lawyer J, et al. Irinote-
can therapy in adults with recurrent or pro-
gressive malignant glioma. J Clin Oncol
1999;17:1516–25.
(23) Zamboni WC, Gajjar AJ, Heideman RL,
Beijnen JH, Rosing H, Houghton PJ, et al.
Phenytoin alters the disposition of topotecan
and N-desmethyl topotecan in a patient with
medulloblastoma. Clin Cancer Res 1998;4:
783–9.
NOTE
Manuscript received April 24, 2002; revised
June 12, 2002; accepted June 14, 2002.
Journal of the National Cancer Institute, Vol. 94, No. 16, August 21, 2002 BRIEF COMMUNICATIONS 1249
